Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (201-210 of 467) with videos related to

Pageof 47
Sort By:
International Journal of Antimicrobial Agents|January 12, 2020
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patientsNadia Galizzi, Andrea Poli, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2016
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ARTNicola Squillace, Patrizia Lorenzini, Giuseppe Lapadula, et al.
BMC Infectious Diseases|February 14, 2014
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation studyGiulia Marchetti, Alessandro Cozzi-Lepri, Camilla Tincati, et al.
AIDS (London, England)|July 16, 2019
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppressionRaffaele Dell'Acqua, Laura Galli, Andrea Poli, et al.
Annals of Clinical Microbiology and Antimicrobials|August 3, 2024
Long-term successfull management of recurrent episodes of nontuberculous mycobacterial infection in an apparently healthy Chinese womanAngelo Roberto Raccagni, Giovanni Mori, Valeria Poletti de Chaurand, et al.
Drug Design, Development and Therapy|December 13, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical PracticeDiana Canetti, Laura Galli, Riccardo Lolatto, et al.
AIDS (London, England)|August 28, 2014
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapyLaura Galli, Vincenzo Spagnuolo, Andrea Poli, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
Pageof 47

Showing results (201-210 of 467) with videos related to

Sort By:
Pageof 47
International Journal of Antimicrobial Agents|January 12, 2020
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patientsNadia Galizzi, Andrea Poli, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2016
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ARTNicola Squillace, Patrizia Lorenzini, Giuseppe Lapadula, et al.
BMC Infectious Diseases|February 14, 2014
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation studyGiulia Marchetti, Alessandro Cozzi-Lepri, Camilla Tincati, et al.
AIDS (London, England)|July 16, 2019
Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppressionRaffaele Dell'Acqua, Laura Galli, Andrea Poli, et al.
Annals of Clinical Microbiology and Antimicrobials|August 3, 2024
Long-term successfull management of recurrent episodes of nontuberculous mycobacterial infection in an apparently healthy Chinese womanAngelo Roberto Raccagni, Giovanni Mori, Valeria Poletti de Chaurand, et al.
Drug Design, Development and Therapy|December 13, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical PracticeDiana Canetti, Laura Galli, Riccardo Lolatto, et al.
AIDS (London, England)|August 28, 2014
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapyLaura Galli, Vincenzo Spagnuolo, Andrea Poli, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The New Microbiologica|July 23, 2005
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavirNicola Gianotti, Elena Seminari, Monica Guffanti, et al.
Pageof 47